San Diego, United States
IconOVir Bio, founded in 2018, is a preclinical-stage biotechnology company headquartered in the United States. The company focuses on pioneering next-generation oncolytic virus therapies to enhance cancer treatment, addressing the limitations found in earlier generations of oncolytic viruses. This cutting-edge platform stems from exclusive technology developed by scientific founder Clodagh O’Shea, Ph.D., at the Salk Institute.
The biotechnology and life sciences sectors are notably competitive, yet IconOVir Bio distinguishes itself through its robust scientific foundation and mission-driven approach to "cure cancer and restore life to every patient everywhere." Following their purposeful vision, they've attracted significant investor interest. Their most recent financial backing—a $77.00M Series A investment on 01 January 2021—secured the support of prominent investors such as Polaris Partners, Wellington Partners, Bellco Capital, Logos Capital, Nextech Invest, Two River, and Vida Ventures.
